{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:23:20Z","timestamp":1782818600014,"version":"3.54.5"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"DOI":"10.13039\/spzbvzpd5szt","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2018A030313138"],"award-info":[{"award-number":["2018A030313138"]}],"id":[{"id":"10.13039\/spzbvzpd5szt","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/spututxs36dv","name":"Guang Dong Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","award":["2021A1515220165"],"award-info":[{"award-number":["2021A1515220165"]}],"id":[{"id":"10.13039\/spututxs36dv","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/spmholddx2tm","name":"Hospital Pharmaceutical Research Fund of Guangdong Province","doi-asserted-by":"publisher","award":["2024A02029, 2022JZ33"],"award-info":[{"award-number":["2024A02029, 2022JZ33"]}],"id":[{"id":"10.13039\/spmholddx2tm","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/spqhl1nvpi1l","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2022-20-12"],"award-info":[{"award-number":["320.6750.2022-20-12"]}],"id":[{"id":"10.13039\/spqhl1nvpi1l","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Osimertinib, the first-line treatment for nonsmall cell lung cancer, has 2 main active metabolites, AZ5104 and AZ7550, which demonstrate potency against wild-type\n                      <jats:italic toggle=\"yes\">epidermal growth factor receptor<\/jats:italic>\n                      mutations. In this study, a simple and sensitive analytical method using high-performance liquid chromatography\u2013tandem mass spectrometry (HPLC\u2013MS\/mass spectrometry) was developed and validated to simultaneously quantify osimertinib and its active metabolites in human plasma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Plasma samples were subjected to protein precipitation with zinc sulfate solution and acetonitrile using osimertinib-\n                      <jats:sup>13<\/jats:sup>\n                      C, d\n                      <jats:sub>3<\/jats:sub>\n                      as an internal standard. The separation was performed on a ThermoScientific Hypersil GOLD C18 column (4.6 \u00d7 50 mm, 5 \u03bcm) with a mobile phase composed of 0.1% formic acid water\u2013acetonitrile through gradient elution. The compounds were monitored using electrospray ionization in the positive mode with multiple reaction monitoring.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Excellent linearity of calibration curves was observed over the ranges of 10\u20131000 ng\u00b7mL\n                      <jats:sup>\u22121<\/jats:sup>\n                      for osimertinib, and 1.5\u2013120 ng\u00b7mL\n                      <jats:sup>\u22121<\/jats:sup>\n                      for AZ7550 and AZ5104 in human plasma. Both within-run and between-run accuracies were within \u00b115%, with the coefficient of variation &lt;15%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      The method met all the validation criteria and was successfully applied to clinical samples from patients with nonsmall cell lung cancer. Furthermore, the correlation between steady-state trough concentrations of osimertinib, AZ5104, and AZ7550 and patients' baseline characteristics were explored. Women exhibited a significantly higher C\n                      <jats:sub>min, ss<\/jats:sub>\n                      for AZ7550 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.023). In addition, body mass index was associated with the C\n                      <jats:sub>min, ss<\/jats:sub>\n                      of both AZ5104 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.047) and AZ7550 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001355","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T15:01:24Z","timestamp":1756220484000},"page":"747-754","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Simultaneous Determination of Osimertinib and its Metabolites in Human Plasma for Clinical Applications Using High-Performance Liquid Chromatography\u2013Tandem Mass Spectrometry"],"prefix":"10.1097","volume":"47","author":[{"given":"Jingjing","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3629-9979","authenticated-orcid":false,"given":"Liuxian","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China;"},{"name":"School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou University City, Guangzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangxi Medical University Cancer Hospital, Nanning, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China;"},{"name":"School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou University City, Guangzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Jing","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Dermatology Hospital, Southern Medical University, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"R1-20251107","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20251107","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20251107","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20251107","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00280-016-3097-4","article-title":"Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations","volume":"78","author":"Mizoguchi","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"R5-20251107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2019.05.013","article-title":"Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer","volume":"134","author":"Hayashi","year":"2019","journal-title":"Lung Cancer"},{"key":"R6-20251107","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bcp.13223","article-title":"Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer","volume":"83","author":"Brown","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"R7-20251107","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","article-title":"Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets","volume":"53","author":"Yu","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"R8-20251107","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R9-20251107","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s40262-023-01293-9","article-title":"Therapeutic drug monitoring of kinase inhibitors in oncology","volume":"62","author":"van der Kleij","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R10-20251107","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.annonc.2022.06.010","article-title":"Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study","volume":"33","author":"Groenland","year":"2022","journal-title":"Ann Oncol"},{"key":"R11-20251107","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00280-016-2992-z","article-title":"Osimertinib western and asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies","volume":"77","author":"Planchard","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"R12-20251107","doi-asserted-by":"crossref","first-page":"1363259","DOI":"10.3389\/fphar.2024.1363259","article-title":"Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach","volume":"15","author":"Liang","year":"2024","journal-title":"Front Pharmacol"},{"key":"R13-20251107","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/cpdd.467","article-title":"Absolute bioavailability of osimertinib in healthy adults","volume":"8","author":"Vishwanathan","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R14-20251107","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"R15-20251107","doi-asserted-by":"crossref","first-page":"122752","DOI":"10.1016\/j.jchromb.2021.122752","article-title":"Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS\/MS in human plasma: application to therapeutic drug monitoring in patients with non-small cell lung cancer","volume":"1175","author":"Zhou","year":"2021","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R16-20251107","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/FTD.0000000000000895","article-title":"An liquid chromatography-tandem mass spectrometry method for the simultaneous determination of afatinib, alectinib, ceritinib, crizotinib, dacomitinib, erlotinib, gefitinib, and osimertinib in human serum","volume":"43","author":"Mukai","year":"2021","journal-title":"Ther Drug Monit"},{"key":"R17-20251107","doi-asserted-by":"crossref","first-page":"123245","DOI":"10.1016\/j.jchromb.2022.123245","article-title":"Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum","volume":"1199","author":"Ishikawa","year":"2022","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R18-20251107","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpba.2018.05.052","article-title":"Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients","volume":"158","author":"Reis","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"R19-20251107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2021.12.028","article-title":"Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry","volume":"527","author":"Xiong","year":"2022","journal-title":"Clin Chim Acta"},{"key":"R20-20251107","doi-asserted-by":"crossref","first-page":"124100","DOI":"10.1016\/j.jchromb.2024.124100","article-title":"Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS\/MS in human plasma and its application to therapeutic drug monitoring in cancer patients","volume":"1237","author":"Zhao","year":"2024","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R21-20251107","doi-asserted-by":"crossref","first-page":"123394","DOI":"10.1016\/j.jchromb.2022.123394","article-title":"Development and validation of a novel LC-MS\/MS method for simultaneous quantitative determination of tyrosine kinase inhibitors in human plasma","volume":"1208","author":"Lou","year":"2022","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R22-20251107","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/pharmaceutics16010005","article-title":"Validation of liquid chromatography coupled with tandem mass spectrometry for the determination of 12 tyrosine kinase inhibitors (TKIs) and their application to therapeutic drug monitoring in adult and pediatric populations","volume":"16","author":"Bellouard","year":"2023","journal-title":"Pharmaceutics"},{"key":"R23-20251107","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00216-020-03031-7","article-title":"Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma","volume":"413","author":"Aghai","year":"2021","journal-title":"Anal Bioanal Chem"},{"key":"R24-20251107","doi-asserted-by":"crossref","first-page":"115159","DOI":"10.1016\/j.jpba.2022.115159","article-title":"A liquid chromatography-tandem mass spectrometry method for simultaneous quantification of thirty-nine tyrosine kinase inhibitors in human plasma","volume":"224","author":"Guo","year":"2023","journal-title":"J Pharm Biomed Anal"},{"key":"R25-20251107","doi-asserted-by":"crossref","first-page":"987","DOI":"10.4155\/bio-2018-0262","article-title":"Determination of osimertinib in human plasma, urine and cerebrospinal fluid","volume":"11","author":"Mitchell","year":"2019","journal-title":"Bioanalysis"},{"key":"R26-20251107","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J Clin Oncol"},{"key":"R27-20251107","first-page":"140","article-title":"ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: clinical characteristics and genotyping methods in a Spanish cohort","volume":"53","author":"Vicente-Baz","year":"2020","journal-title":"Rev Esp Patol"},{"key":"R30-20251107","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-016-3232-2","article-title":"Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer","volume":"79","author":"Imai","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"R31-20251107","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/1759-7714.13018","article-title":"Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: a prospective observational study","volume":"10","author":"Ono","year":"2019","journal-title":"Thorac Cancer"},{"key":"R32-20251107","first-page":"100526","article-title":"Switch to EGFR-TKI after upfront platinum doublet induction therapy in non-small cell lung cancer (NSCLC) patients with EGFR (Epidermal Growth Factor Receptor) mutation: a multicentre retrospective study","volume":"31","author":"Almeida","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"R33-20251107","doi-asserted-by":"crossref","first-page":"e21078","DOI":"10.1200\/JCO.2021.39.15_suppl.e21078","article-title":"The prognostic role of body-mass index (BMI) for advanced EGFR positive non-small cell lung cancer (NSCLC) patients treated with osimertinib","volume":"39","author":"De Giglio","year":"2021","journal-title":"J Clin Oncol"},{"key":"R34-20251107","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/1759-7714.12275","article-title":"Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer","volume":"7","author":"Sun","year":"2016","journal-title":"Thorac Cancer"},{"key":"R35-20251107","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3904\/kjim.2015.062","article-title":"Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations","volume":"31","author":"Park","year":"2016","journal-title":"Korean J Intern Med"},{"key":"R36-20251107","doi-asserted-by":"crossref","first-page":"187","DOI":"10.14740\/wjon1244","article-title":"Low body mass index is an independent prognostic factor in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitor","volume":"10","author":"Minami","year":"2019","journal-title":"World J Oncol"},{"key":"R37-20251107","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1007\/s11095-022-03355-2","article-title":"Exposure-response analysis of osimertinib in EGFR mutation positive non-small cell lung cancer patients in a real-life setting","volume":"39","author":"Boosman","year":"2022","journal-title":"Pharm Res"},{"key":"R38-20251107","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/ijc.34742","article-title":"Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer","volume":"154","author":"van Veelen","year":"2024","journal-title":"Int J Cancer"},{"key":"R39-20251107","doi-asserted-by":"crossref","first-page":"725","DOI":"10.21873\/anticanres.16211","article-title":"Relationship between osimertinib concentration and clinical response in Japanese patients with non-small cell lung cancer","volume":"43","author":"Yamazaki","year":"2023","journal-title":"Anticancer Res"},{"key":"R40-20251107","doi-asserted-by":"crossref","first-page":"17588359221103212","DOI":"10.1177\/17588359221103212","article-title":"Improving the tolerability of osimertinib by identifying its toxic limit","volume":"14","author":"Agema","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"R41-20251107","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3390\/pharmaceutics14091844","article-title":"Exposure-response analysis of osimertinib in patients with advanced non-small-cell lung cancer","volume":"14","author":"Rodier","year":"2022","journal-title":"Pharmaceutics"},{"key":"R42-20251107","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3390\/biomedicines11092501","article-title":"A prospective cohort study assessing the relationship between plasma levels of osimertinib and treatment efficacy and safety","volume":"11","author":"Fukuhara","year":"2023","journal-title":"Biomedicines"},{"key":"R43-20251107","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1159\/000531840","article-title":"Successful treatment with osimertinib based on therapeutic drug monitoring in a hemodialysis patient with non-small cell lung cancer: a case report","volume":"16","author":"Tabata","year":"2023","journal-title":"Case Rep Oncol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:00:36Z","timestamp":1762542036000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001355","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"2025-01-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}